PIPE-791 is Contineum Therapeutics’ novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid 1 receptor (LPA1).?By selectively blocking LPA1 receptor activity, an LPA1 antagonist such as PIPE-791 may prevent or reverse the maladaptive changes in the nervous system that initiate and maintain the chronic pain state.? https://lnkd.in/g_PSfquW #Biotech #Neuro #IND #FDA #chronicpain
Contineum Therapeutics
制药业
San Diego，CA 3,414 位关注者
Focusing on the NI&I space by creating precision small molecules that seek to alter the course of clinical impairment.
关于我们
Contineum Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with high unmet need. Contineum targets biological pathways associated with specific clinical disabilities, that once modulated, can demonstrably impact the course of disease.
- 网站
-
https://www.contineum-tx.com/
Contineum Therapeutics的外部链接
- 所属行业
- 制药业
- 规模
- 11-50 人
- 总部
- San Diego，CA
- 类型
- 私人持股
- 创立
- 2017
地点
-
主要
获取路线
US，CA，San Diego
Contineum Therapeutics员工
动态
-
#CTNM is expanding the development of PIPE-791 into chronic pain, with an exploratory Phase 1b study for osteoarthritis (OA) and low back pain (LBP) expected to begin in 1Q25. https://lnkd.in/g_PSfquW #Biotech #neuro #chronicpain #IND #FDA
-
-
Contineum Therapeutics will be attending two investor conferences in November. Carmine Stengone, our President & CEO, will present at the Stifel Healthcare Conference on Monday, November 18, 2024, at 4:10 p.m. ET in New York.?We are also attending the Jefferies London Healthcare Conference on Thursday, November 21, 2024. https://lnkd.in/geTqsT_A #biotech #healthcare #StifelHealthcareConference #JefferiesHealthcareConference
-
-
Today, we announced our 3rd quarter 2024 financial results and recent highlights.?Read more here: https://lnkd.in/gGBqt4rz #biotech #healthcare #neuro
-
-
Biocom California’s San Diego Life Science CEO Summit returns for its second year, designed exclusively for CEOs in the life science industry. Carmine Stengone, our President and CEO will be a featured panel speaker at the “2024 IPOs: Lessons learned and Next Chapter” session on Thursday, November 7 at 2:15 pm. Learn more here: https://lnkd.in/gH5qtNEA #biotech #healthcare #BioComCEOsummit
-
-
The Contineum Therapeutics team will present at two investor conferences next month: the Morgan Stanley 22nd Annual Global Healthcare Conference and the H.C. Wainwright & Co., LLC 26th Annual Global Investment Conference. More details can be found here: https://lnkd.in/gYQ5mjR7 #Biotech #Neuro #MorganStanley2024 #HCW2024
-
-
Are you ready for a change? We're hiring! The Contineum Therapeutics team is currently looking for a project manager to support our pre-clinical/clinical programs. More information on this open position and how to apply can be found on our Careers page. https://lnkd.in/geD-4NU5 #biotech #hiring #neuroscience
-
-
We're hiring! The Contineum Therapeutics team is currently looking for an experienced Regulatory Affairs professional to join our fast-paced biotechnology Company!?More information on this open position and how to apply can be found on our Careers page. https://lnkd.in/gtt9QfFA #biotech #hiring #neuroscience
-
-
Today, we announced our 2nd quarter 2024 financial results and corporate update. Read more here: https://lnkd.in/gm6ciWTy #biotech #healthcare
-
-
Last week, at the IASP 2024 World Congress on Pain, we presented the effects of our lead asset, PIPE-791, a novel LPA1R antagonist, on brain activation in a nonhuman primate model of peripheral neuropathy. Our findings showed that PIPE-791 significantly reduced activation in brain regions associated with pain perception, suggesting that blocking LPA1 may be a promising approach to treating neuropathic pain. Learn more here: https://lnkd.in/gxMrxqEy #IASP #pain
-